Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 361 clinical trials
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and …

serum bilirubin level
sarcoma
bone metastases
lymphocyte count
international normalized ratio (inr)
  • 0 views
  • 19 Feb, 2024
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

This trial is a randomized, double-blind, multinational Phase III study to evaluate the efficacy and safety of preemptive treatment with FTD/TPI compared with administration of placebo as follow-up, which is the standard of care, in patients who underwent curative resection of colorectal cancer and then tested positive for ctDNA.

diarrhea
platelet count
metastasis
adenocarcinoma
colorectal adenocarcinoma
  • 0 views
  • 19 Feb, 2024
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by …

secondary acute myeloid leukemia
t-aml
myelodysplastic syndrome acute myeloid leukemia
plasma creatinine
aml
  • 0 views
  • 19 Feb, 2024
AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive Metastatic NSCLC

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcome when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for …

pemetrexed
neoplasms by site
metastatic non-small cell lung cancer
measurable disease
metastatic cancer
  • 0 views
  • 19 Feb, 2024
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

This phase II trial studies how well decitabine with ruxolitinib or fedratinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, …

white blood cell count
hypoxia
polycythemia
essential thrombocythemia
blood cell counts
  • 0 views
  • 19 Feb, 2024
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

In patients with locally advanced oral squamous cell carcinoma (OSCC), due to the large tumor burden and neck lymph node metastasis, comprehensive treatment is recommended, including surgery, radiotherapy, chemotherapy and others. Pre-operative inductive therapy can reduce tumor volume, increase organ retention rate, and reduce distant metastasis rate.

vascular endothelial growth factor
neovascularization
white blood cell count
tumor angiogenesis
hypoxia
  • 0 views
  • 19 Feb, 2024
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

ros1
liquid biopsy
pembrolizumab
pemetrexed
adjuvant therapy
  • 0 views
  • 19 Feb, 2024
The Application of Real-Time Near-infrared Imaging in Gynecological Surgery

Removing in situ and metastasis lesions completely during gynecological surgery is central to reduce the recurrence and death, and the identification of lesions in traditional gynecological surgery often depends on the experience of surgeons.

iia2
ovarian cyst
cervical cancer
pelvic lymphadenectomy
lymphadenectomy
  • 0 views
  • 19 Feb, 2024
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Background Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis.

electroencephalogram
solid tumor
pancreatic cancer
renal function
cancer
  • 0 views
  • 19 Feb, 2024
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors

Hepatic metastases are common in solid cancers (up to 30% of patients with colorectal cancer and up to 50% of patients during their follow-up). The incidence of primary liver cancer increases due to the increase in chronic liver diseases induced by excessive alcohol consumption, hepatitis B and C viruses, and …

liver cancer
chelates
liver diseases
metastasis
stereotactic radiation therapy
  • 0 views
  • 19 Feb, 2024